Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Carcinoma, Renal Cell 32Sarcoma 29Neoplasm Metastasis 17Ovarian Neoplasms 10Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Kidney Neoplasms 6Recurrence 5Lung Neoplasms 5Liposarcoma 5Thyroid Neoplasms 4Melanoma 4Leiomyosarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Pancreatic Neoplasms 3Neurofibrosarcoma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Chondrosarcoma, Extraskeletal Myxoid 3Advanced Cancers 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solitary Fibrous Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × pazopanib × Clear all
NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
44 enrolled 17 charts
EndocrineNET

Neuroendocrine Tumors

NCT01099540 2015-12-29

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Samsung Medical Center

Phase 2 Completed
37 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡